Irinotecan Phares

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Phares, is a topoisomerase I inhibitor presented as an injectable formulation for intravenous use. It is employed in the treatment of metastatic and advanced colorectal cancer in adult patients.

GNH USA supplies Irinotecan Phares as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Irinotecan Phares is a topoisomerase I inhibitor used in colorectal cancer therapy.

Metastatic colorectal cancer: improves overall survival when used in combination chemotherapy. Advanced colorectal cancer: reduces tumor progression and disease burden. Colorectal adenocarcinoma: incorporated into standard regimens such as FOLFIRI to enhance response rates.

Irinotecan may cause a range of adverse reactions.

Common Side Effects: - Nausea and vomiting - Diarrhea - Neutropenia (decreased white blood cell count) - Fatigue

Serious or Rare Side Effects: - Severe neutropenia with fever - Life‑threatening diarrhea (colitis) - Allergic or anaphylactic reactions

Careful monitoring is required when administering Irinotecan Phares. - Monitor blood counts: perform regular CBC to detect neutropenia. - Assess liver function: check hepatic enzymes before and during therapy. - Evaluate for bowel obstruction: avoid use in patients with known obstruction. - Avoid concurrent strong CYP3A4 inhibitors: may increase drug exposure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan interacts with several medicines that may alter its safety or efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase toxicity. - UGT1A1 inhibitors (e.g., atazanavir): raise active metabolite levels. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other myelosuppressive agents: additive bone‑marrow suppression. - Diuretics: potential electrolyte disturbances.